Valeant, Lundbeck, J&J, GSK . . .
Epilepsy Pie Slices Will Narrow - but Players Lining Up Anyway
By Randy Osborne
Monday, August 31, 2009
Valeant Pharmaceuticals Inc.'s missed Phase IIa endpoint last week with retigabine for pain in postherpetic neuralgia leaves intact the promise proven in Phase III for epilepsy - albeit a promise somewhat limited by the dosing schedule of the potassium channel opener, subject of a lucrative year-ago deal with GlaxoSmithKline plc.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.